425 related articles for article (PubMed ID: 34112739)
1. Immunotherapy using IgE or CAR T cells for cancers expressing the tumor antigen SLC3A2.
Pellizzari G; Martinez O; Crescioli S; Page R; Di Meo A; Mele S; Chiaruttini G; Hoinka J; Batruch I; Prassas I; Grandits M; López-Abente J; Bugallo-Blanco E; Ward M; Bax HJ; French E; Cheung A; Lombardi S; Figini M; Lacy KE; Diamandis EP; Josephs DH; Spicer J; Papa S; Karagiannis SN
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34112739
[TBL] [Abstract][Full Text] [Related]
2. Chimeric Antigen Receptors Based on Low Affinity Mutants of FcεRI Re-direct T Cell Specificity to Cells Expressing Membrane IgE.
Ward DE; Fay BL; Adejuwon A; Han H; Ma Z
Front Immunol; 2018; 9():2231. PubMed ID: 30364107
[TBL] [Abstract][Full Text] [Related]
3. Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors.
Stock S; Benmebarek MR; Kluever AK; Darowski D; Jost C; Stubenrauch KG; Benz J; Freimoser-Grundschober A; Moessner E; Umana P; Subklewe M; Endres S; Klein C; Kobold S
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35902133
[TBL] [Abstract][Full Text] [Related]
4. Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcɛRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity.
Rudman SM; Josephs DH; Cambrook H; Karagiannis P; Gilbert AE; Dodev T; Hunt J; Koers A; Montes A; Taams L; Canevari S; Figini M; Blower PJ; Beavil AJ; Nicodemus CF; Corrigan C; Kaye SB; Nestle FO; Gould HJ; Spicer JF; Karagiannis SN
Clin Exp Allergy; 2011 Oct; 41(10):1400-13. PubMed ID: 21569129
[TBL] [Abstract][Full Text] [Related]
5. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
[TBL] [Abstract][Full Text] [Related]
6. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
Front Immunol; 2021; 12():665970. PubMed ID: 34475869
[TBL] [Abstract][Full Text] [Related]
7. High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy.
Rataj F; Jacobi SJ; Stoiber S; Asang F; Ogonek J; Tokarew N; Cadilha BL; van Puijenbroek E; Heise C; Duewell P; Endres S; Klein C; Kobold S
Br J Cancer; 2019 Jan; 120(1):79-87. PubMed ID: 30429531
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice.
Li T; Wang J
BMC Cancer; 2020 Jul; 20(1):678. PubMed ID: 32689954
[TBL] [Abstract][Full Text] [Related]
9. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z
Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445
[TBL] [Abstract][Full Text] [Related]
10. An immunologically relevant rodent model demonstrates safety of therapy using a tumour-specific IgE.
Josephs DH; Nakamura M; Bax HJ; Dodev TS; Muirhead G; Saul L; Karagiannis P; Ilieva KM; Crescioli S; Gazinska P; Woodman N; Lombardelli C; Kareemaghay S; Selkirk C; Lentfer H; Barton C; Canevari S; Figini M; Downes N; Dombrowicz D; Corrigan CJ; Nestle FO; Jones PS; Gould HJ; Blower PJ; Tsoka S; Spicer JF; Karagiannis SN
Allergy; 2018 Dec; 73(12):2328-2341. PubMed ID: 29654623
[TBL] [Abstract][Full Text] [Related]
11. Activity of Anti-CD19 Chimeric Antigen Receptor T Cells Against B Cell Lymphoma Is Enhanced by Antibody-Targeted Interferon-Alpha.
Young PA; Yamada RE; Trinh KR; Vasuthasawat A; De Oliveira S; Yamada DH; Morrison SL; Timmerman JM
J Interferon Cytokine Res; 2018 Jun; 38(6):239-254. PubMed ID: 29920129
[TBL] [Abstract][Full Text] [Related]
12. Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer.
Jiang H; Shi Z; Wang P; Wang C; Yang L; Du G; Zhang H; Shi B; Jia J; Li Q; Wang H; Li Z
J Natl Cancer Inst; 2019 Apr; 111(4):409-418. PubMed ID: 30203099
[TBL] [Abstract][Full Text] [Related]
13. Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance.
Muller YD; Ferreira LMR; Ronin E; Ho P; Nguyen V; Faleo G; Zhou Y; Lee K; Leung KK; Skartsis N; Kaul AM; Mulder A; Claas FHJ; Wells JA; Bluestone JA; Tang Q
Front Immunol; 2021; 12():686439. PubMed ID: 34616392
[TBL] [Abstract][Full Text] [Related]
14. Folate receptor 1 (FOLR1) targeted chimeric antigen receptor (CAR) T cells for the treatment of gastric cancer.
Kim M; Pyo S; Kang CH; Lee CO; Lee HK; Choi SU; Park CH
PLoS One; 2018; 13(6):e0198347. PubMed ID: 29874279
[TBL] [Abstract][Full Text] [Related]
15. Targeting SLC1A5 and SLC3A2/SLC7A5 as a Potential Strategy to Strengthen Anti-Tumor Immunity in the Tumor Microenvironment.
Nachef M; Ali AK; Almutairi SM; Lee SH
Front Immunol; 2021; 12():624324. PubMed ID: 33953707
[TBL] [Abstract][Full Text] [Related]
16. Chimeric cytokine receptor enhancing PSMA-CAR-T cell-mediated prostate cancer regression.
Weimin S; Abula A; Qianghong D; Wenguang W
Cancer Biol Ther; 2020 Jun; 21(6):570-580. PubMed ID: 32208880
[No Abstract] [Full Text] [Related]
17. T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells.
Yang D; Sun B; Dai H; Li W; Shi L; Zhang P; Li S; Zhao X
J Immunother Cancer; 2019 Jul; 7(1):171. PubMed ID: 31288857
[TBL] [Abstract][Full Text] [Related]
18. T Cells Expressing NKG2D CAR with a DAP12 Signaling Domain Stimulate Lower Cytokine Production While Effective in Tumor Eradication.
Ng YY; Tay JCK; Li Z; Wang J; Zhu J; Wang S
Mol Ther; 2021 Jan; 29(1):75-85. PubMed ID: 32956627
[TBL] [Abstract][Full Text] [Related]
19. [Construction of a new anti-CD123 chimeric antigen receptor T cells and effect of anti-acute myeloid leukemia].
Wang ZZ; Lu Y; Xu YX; Xing HY; Tang KJ; Tian Z; Rao Q; Wang M; Xiong DS; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2020 Mar; 41(3):192-197. PubMed ID: 32311887
[No Abstract] [Full Text] [Related]
20. Accurate control of dual-receptor-engineered T cell activity through a bifunctional anti-angiogenic peptide.
Zhang E; Gu J; Xue J; Lin C; Liu C; Li M; Hao J; Setrerrahmane S; Chi X; Qi W; Hu J; Xu H
J Hematol Oncol; 2018 Mar; 11(1):44. PubMed ID: 29558951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]